Phathom Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Phathom Pharmaceuticals, Inc. | PHAT - | $18.00-$20.00 | $19.00 | $22.50 | 9.6 million | 10/25/2019 |
| Goldman Sachs, Jefferies, Evercore ISI | ||||||
Co-Manager(s): Needham & Co. | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-09-30 Terms Added 2019-10-15 | ||||||
Phathom Pharmaceuticals, Inc. Quote & Chart - Click for current quote - PHAT
IPO Boutique aggregates information on public companies and private companies, such as "PHAT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Phathom Pharmaceuticals, Inc. (adapted from Phathom Pharmaceuticals, Inc. prospectus):
They are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PHAT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.